GB Sciences, Inc. (GBLX)
| Market Cap | 22.04M |
| Revenue (ttm) | 1.34M |
| Net Income (ttm) | -11.87M |
| Shares Out | 280.97M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $0.0751 |
| Previous Close | $0.0800 |
| Change ($) | -0.0049 |
| Change (%) | -6.13% |
| Day's Open | 0.0880 |
| Day's Range | 0.0750 - 0.0880 |
| Day's Volume | 418,685 |
| 52-Week Range | 0.0151 - 0.13 |
News
LAS VEGAS, NV / ACCESSWIRE / January 12, 2021 / GB Sciences, Inc. (OTCQB:GBLX) completed the sale of its remaining interest in GB Sciences Louisiana LLC ("GBSLA") on December 16, 2020. In Nove...
About GBLX
GB Sciences engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
| Industry Biotechnology | |
| CEO John Poss | Employees 23 |
| Stock Exchange OTCMKTS | Ticker Symbol GBLX |
Financial Performance
In 2019, GB Sciences's revenue was $3.12 million, a decrease of -9.67% compared to the previous year's $3.45 million. Losses were -$12.37 million, -47.69% less than in 2018.